The same new drug, four different verdicts — comparing NICE (UK), IQWiG/G-BA (Germany), CMS (US), and PBAC (Australia) reimbursement pathways from submission to patient access
Regulatory approval (EMA in Europe, FDA in the US, TGA in Australia) answers a narrow question — is this technology safe and effective enough to be sold at all? Reimbursement is a separate, later, and entirely national decision about whether a health system will pay for it, at what price, and for which patients. A drug can be legally on the market in all four jurisdictions and still be functionally unavailable to most patients in one of them for a year or more.
A regulator like the EMA or FDA asks: does this technology work, and is it acceptably safe, for the claimed indication? An HTA or payer body asks an entirely different question: given everything else we could spend this money on, is funding this technology, at this price, a good use of finite health-system resources? The two processes run on different legal authorities, different timelines, and often reach different conclusions about the same clinical trial data — a drug NICE calls "not cost-effective" may be exactly the same drug the FDA called safe and effective six months earlier.
This split is precisely why a single global "approval" event does not translate into a single global "access" event. Four systems, four independent value judgments, four different clocks.
Manufacturers rarely file everywhere simultaneously by default — they sequence launches deliberately. Germany's AMNOG system grants free pricing for the first 12 months, making it an attractive early-launch market to set a favorable initial reference price. That German list price, however, does not stay contained: many other countries — inside and outside Europe — use international reference pricing baskets that peg their own negotiations partly to prices observed in a handful of reference countries.
International reference pricing means a manufacturer's pricing decision in one country can silently constrain its negotiating position in a dozen others. A launch sequencing mistake in a single market can depress achievable prices globally for years.
From January 2025, the EU's Health Technology Assessment Regulation phases in a Joint Clinical Assessment (JCA) — a single shared clinical-evidence review conducted once at EU level for certain oncology and advanced-therapy products, intended to reduce duplicated dossier work across national bodies like Germany's G-BA. Crucially, the JCA only ever covers the clinical-evidence question; each member state, including Germany, still runs its own separate appraisal of cost-effectiveness and makes its own final pricing and reimbursement decision. The four-system comparison in this tool therefore remains fully valid even as evidence generation slowly harmonizes at the clinical layer.
NICE, Germany's joint G-BA/IQWiG system, CMS, and PBAC do not just differ in speed — they differ in what they fundamentally ask a manufacturer to prove. NICE wants a full economic model; Germany wants a demonstration of added clinical benefit over a specified comparator; the US has no single mandatory national HTA gate for drugs at all; Australia wants an economic case similar in spirit to the UK's.
Both NICE and PBAC require manufacturers to submit a full health-economic model — typically a Markov or partitioned-survival model — projecting quality-adjusted life years (QALYs) gained and incremental costs versus the relevant standard of care over a lifetime horizon. Every assumption (discount rates, extrapolation method, utility values, comparator choice) is scrutinized by an independent academic evidence review group before the appraisal committee ever sees the headline ICER.
Under §35a SGB V, IQWiG (or occasionally G-BA itself) assesses the new drug's "Zusatznutzen" — added benefit — strictly against a "zweckmäßige Vergleichstherapie" (appropriate comparator therapy) chosen by G-BA in advance. The output is a categorical rating (major, considerable, minor, non-quantifiable, none, or less benefit), not a cost-per-QALY figure. Cost-effectiveness modelling is deliberately absent from this first stage — cost only enters later, during price negotiation.
The US remains structurally unique among the four: there is no single mandatory national HTA body a manufacturer must clear to get a drug covered. Coverage is negotiated separately with thousands of private payers and PBMs, with only the nonprofit ICER offering an independent (non-binding) value assessment — a fragmentation that shapes everything downstream.
PBAC's submission process runs on a fixed cycle of scheduled meetings (typically March, July, and November), so timing a dossier to miss a cycle by even a few days can add another four months of pure calendar delay before the same evidence is even considered — a purely procedural friction point that does not exist in NICE's more continuously rolling technology appraisal process. PBAC also operates the Life Saving Drugs Program as a separate high-cost, high-need pathway outside the standard cost-utility route, functionally similar in spirit to NICE's Highly Specialised Technologies programme for very rare conditions.
This is where the four systems diverge most starkly in method. NICE and PBAC anchor decisions to (semi-)explicit cost-per-QALY thresholds. Germany separates the benefit question entirely from the cost question. CMS historically avoided any formal cost-effectiveness test — though the 2022 Inflation Reduction Act is now pulling US policy visibly toward HTA-style methodology for the first time.
NICE's widely cited £20,000–30,000 per QALY range (with substantially higher effective thresholds for end-of-life treatments and the Highly Specialised Technologies route, sometimes exceeding £100,000/QALY) functions as a rough decision rule, not a rigid law — committees weigh uncertainty, severity, and innovation alongside the number. PBAC operates similarly with an unpublished implicit range, deliberately never codified so as to preserve negotiating flexibility.
This is the single most consequential structural difference in the comparator: in Germany, essentially every newly approved drug is available to patients from day one, at the manufacturer's own list price, regardless of what IQWiG eventually concludes about added benefit. The benefit assessment determines the price the statutory health insurers will pay afterward — not whether the drug is on the market. Patients are never waiting on a German cost-effectiveness verdict the way they may be waiting on a NICE or PBAC one.
Historically, CMS coverage determinations for drugs asked only whether a treatment was "reasonable and necessary" for the diagnosis or treatment of illness — with no statutory mandate to weigh cost-effectiveness at all, and Medicare was legally barred from directly negotiating drug prices. The Inflation Reduction Act's Medicare Drug Price Negotiation Program breaks with that history: starting with a small number of high Medicare-spend drugs, CMS now negotiates a "maximum fair price," explicitly informed by clinical benefit and comparative-effectiveness evidence — a structural (if still narrow) step toward the other three systems' methodology.
Four philosophies, one underlying tension: efficiency-maximizing thresholds (NICE, PBAC) versus benefit-first/price-second sequencing (Germany) versus a historically market-plural, now slowly centralizing system (US). No approach eliminates the trade-off between speed, rigor, and affordability — each system just picks a different point on that triangle.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| NICE (UK) | |||
| G-BA / IQWiG (Germany) | |||
| CMS (US) | |||
| PBAC (Australia) |
Almost nobody pays list price. Behind every published price sits a second, usually confidential, negotiated net price — arrived at through mechanisms that differ enormously in transparency and government leverage across the four systems.
NICE routinely conditions a positive recommendation on a Patient Access Scheme or Commercial Access Agreement — a confidential discount, dose cap, or outcomes-based rebate that lowers the effective price below the published list price without disclosing the exact figure publicly. Australia's Special Pricing Arrangements serve an almost identical function for PBS-listed medicines: the publicly quoted PBS price and the price the government actually pays can differ substantially.
Once IQWiG's added-benefit rating is finalized, the manufacturer and GKV-Spitzenverband (the umbrella body for statutory health insurers) have six months to agree a reimbursement price consistent with that rating; failing agreement, the case goes to binding arbitration. This is a mature, rules-based negotiation process running for over a decade. The US, by contrast, has essentially never had a government-run price negotiation for branded drugs until the IRA — before 2026, US net prices emerged entirely from opaque, decentralized rebate negotiations between manufacturers and thousands of private PBMs and insurers.
External reference pricing ties these negotiations together across borders: a low negotiated German or list price can quietly re-enter another country's reference basket months later, which is precisely why manufacturers treat global launch sequencing as price architecture, not just logistics.
Collapsing all four pathways into a single number — days from regulatory approval to patients actually being able to get the treatment — produces one of the starkest comparative statistics in health policy: the same drug can reach patients in a matter of days in one system and take well over a year in another.
Germany's near-instant nominal access is real, but uptake still depends on physician prescribing incentives and the reference-pricing group a drug eventually lands in. The US often shows the fastest nominal market entry of all four systems — no national HTA gate stands between approval and a product hitting pharmacy shelves — yet high patient cost-sharing, narrow formularies, step therapy, and prior authorization requirements mean a meaningful share of eligible US patients face de facto delays or denials that a simple "days to listing" metric never captures.
Germany optimizes for speed by decoupling access from cost-effectiveness review entirely, accepting higher initial system spend. NICE and PBAC optimize for fiscal discipline and consistency via explicit-ish thresholds, accepting slower, more contested access for genuinely novel technologies. The historical US model optimized for speed and choice at the cost of price discipline and system-wide affordability, a trade-off the IRA is now partially renegotiating. Every comparator dashboard like this one is ultimately visualizing the same underlying policy choice, made four different ways.
No health system has solved the trilemma of fast access, rigorous value assessment, and fiscal sustainability simultaneously — each of the four systems compared here has explicitly, if implicitly, chosen which two of the three to prioritize.
Every simplified model like this one strips away real texture: within-country variation (a NICE-approved drug can still face slower local NHS funding and formulary decisions after a positive national appraisal; PBS-listed drugs in Australia still require individual state and hospital formulary uptake), disease-area-specific fast lanes (oncology and orphan/rare-disease drugs often move faster than the system-wide median in every jurisdiction), and the fact that timelines shift with policy reform — the IRA's Medicare negotiation program is barely underway and Germany's AMNOG rules have already been revised multiple times since 2011. Treat every number on this page as illustrative of relative system behavior, not as a live regulatory reference.